Abstract:Abstract Transcription factors (TFs) are key regulators of homeostasis and cancer. Recent advances in pharmacological targeting of TFs makes them valuable targets in various diseases, but systems-level understanding of the function and regulation of TFs from different families in cancers remains lacking. Our lab and collaborators have been developing new small molecules to modulate the functions of key regulators of the circadian clock BMAL1 and CLOCK, which are bHLH family TFs that activate gene expression by binding to a DNA motif called E-box, with a consensus sequence of CANNTG. E-boxes are ubiquitous in the genome and broadly regulate essential physiological processes of the cell, but their molecular biology in cancer is largely unknown. In the current work we tested the ability of small molecules to regulate the expression of BMAL1 and CLOCK target genes. Across different cell lines of various cancer types, we found that stabilization of one of the negative regulators of CLOCK, CRY2, by our novel compound called SHP1705, is the most consistent to suppress canonical BMAL1 target genes. GO and GSEA analysis of RNA-seq data shows that SHP1705 also significantly changed most core regulators of circadian rhythms as well as other E-box-binding proteins. However, SHP1705 has IC50 values above 10μM in most tested cells, creating a challenge for efficacy in a clinical setting. Because BMAL1 requires the proteasome to sustain the turnover of a transcription burst, we hypothesized proteasome inhibitors (PI) MG132 and carfilzomib may synergize with SHP1705. Consequently, we found strong synergy with both PIs. Analysis of TF-target genes in combination-treated cells reveals significant changes in expression profiles, suggesting that these genes are regulated by E-box, and other related/alternative promoter elements: CCAAT-box, CG-rich motifs, and ATGGC. Co-enrichment of these elements revealed the components of E-box containing promoters and showed potential properties of E-box-regulated gene expression. Co-existence of these motifs in the same proximal promoter also potentially allows RNAPII multiple choices of alternative promoters and could promote expression of variants in cancer cells. Our results support the necessity of inhibiting the whole promoter and provide an example of how to approach designer pharmacological strategies to achieve this purpose. Citation Format: Yuanzhong Pan, Heinz-Josef Lenz, Evanthia Roussos Torres, Steve A. Kay. Pharmacological targeting of circadian clock genes reveals regulatory mechanisms of E-box regulated genes in cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3715.

PIWIL1 Suppresses Circadian Rhythms Through GSK3β‐induced Phosphorylation and Degradation of CLOCK and BMAL1 in Cancer Cells

Cancer/testis Antigen PIWIL2 Suppresses Circadian Rhythms by Regulating the Stability and Activity of BMAL1 and CLOCK

PIWIL2 Stabilizes Β-Catenin to Promote Cell Cycle and Proliferation in Tumor Cells

The MiR-135b–BMAL1–YY1 Loop Disturbs Pancreatic Clockwork to Promote Tumourigenesis and Chemoresistance

PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells

The Circadian Clock Gene Bmal1 Acts As a Potential Anti-Oncogene in Pancreatic Cancer by Activating the P53 Tumor Suppressor Pathway.

PIWIL1 Destabilizes Microtubule by Suppressing Phosphorylation at Ser16 and RLIM-mediated Degradation of Stathmin1

Nucleus-exported CLOCK acetylates PRPS to promote de novo nucleotide synthesis and liver tumour growth

The Circadian Protein PER1 Modulates the Cellular Response to Anticancer Treatments

Disruption of the Clock Component Bmal1 in Mice Promotes Cancer Metastasis through the PAI‐1‐TGF‐β‐myoCAF‐Dependent Mechanism

PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.

The interplay between the PI3K/AKT pathway and circadian clock in physiologic and cancer‐related pathologic conditions

REGγ Regulates Circadian Clock by Modulating BMAL1 Protein Stability

Effects of the Biological Clock Gene Bmal1 on Tumour Growth and Anti-Cancer Drug Activity.

Dysregulation, Functional Implications, and Prognostic Ability of the Circadian Clock Across Cancers

Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle

E3 Ubiquitin Ligase HRD1 Modulates the Circadian Clock Through Regulation of BMAL1 Stability

CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells

Abstract 3715: Pharmacological targeting of circadian clock genes reveals regulatory mechanisms of E-box regulated genes in cancer

Circadian rhythm regulates the function of immune cells and participates in the development of tumors

The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis